Dermatology Safety

Data at week 12



IN PLAQUE PSORIASIS TRIALS

Adverse reactions that occurred in ≥1% of Taltz patients and more frequently than with placebo in plaque psoriasis registration trials1

Safety adverse 12 week
Safety infections 12 week

The most frequent injection site reactions were erythema and pain. Most injection site reactions were mild to moderate in severity and did not lead to discontinuation of Taltz.


SAFETY DATA FROM SPIRIT-P1 AND -P2 TRIALS

Overall, patients with psoriatic arthritis had a safety profile consistent with that of patients with plaque psoriasis in UNCOVER-1, -2, and -3 trials, except for frequency of influenza (Taltz 1.3%, placebo 0.4%) and conjunctivitis (Taltz 1.3%, placebo 0%).


ADDITIONAL ACTIVE COMPARATOR SAFTEY INFORMATION

In the 2 clinical trials that included Enbrel, an active comparator, the rate of serious adverse events during weeks 0 to 12 was 2% with Taltz and 0.7% with US-approved Enbrel, and the rate of discontinuation from adverse events was 2% with Taltz and 0.7% with US-approved Enbrel.

Data at week 60



IN PLAQUE PSORIASIS TRIALS

Adverse events during weeks 0 to 60 with Taltz vs placebo from plaque psoriasis trials1

Safety adverse 0-60

Among those treated with Taltz, the exposure-adjusted incident rates of adverse events from 13 to 60 weeks were lower than the exposure-adjusted incidence rates from 0 to 12 weeks (1.0 vs 2.5 per subject-year of follow-up).

Long-term data



Safety in Taltz clinical trial participants studied for up to 6 years2-4

In the plaque psoriasis and psoriatic arthritis safety population, 6989 patients across 15 clinical trials received Taltz, with a total exposure of 16,586 patient-years (PY).

  • In psoriatic arthritis trials, the average duration of exposure was 449 days, with 258 patients having at least 2 years’ exposure
  • In plaque psoriasis trials, the average duration of exposure was 946 days, with 2981 patients having at least 3 years’ exposure
Safety long term siae

The safety profile observed in patients with psoriatic arthritis who were treated with Taltz is consistent with the safety profile in patients with plaque psoriasis. The exceptions include frequencies of influenza (1.3%) and conjunctivitis (1.3%).

Certain adverse events, such as MACE and malignancy, require longer observation periods and larger patient exposure to ascertain risk. Lilly is conducting continued long-term safety studies, including post-marketing studies, to continue to evaluate the safety of Taltz.

The reported safety population includes all dosing arms of the phase 1-3 psoriasis clinical trials. Not all patients received the recommended dosing regimen consistent with the FDA-approved label.


References: 1. Taltz [package insert]. Indianapolis, IN: Eli Lilly and Company; 2018. 2. Data on file. Lilly USA, LLC. TAL20171211A. 3. Data on file. Lilly USA, LLC. DOF-IX-US-0019. 4. Mease P, Roussou E, Burmester GR, et al. Safety of ixekizumab in patients with psoriatic arthritis: results from a pooled analysis of three clinical trials. Arth Care Res. 2018 (Epub). doi:10.1002/acr.23738.

Indications and Important Safety Information
Indications

Taltz is indicated for your adult patients with active psoriatic arthritis (PsA).

Taltz is also indicated for your adult patients with moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.

Important Safety Information
CONTRAINDICATIONS
Taltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.

WARNINGS AND PRECAUTIONS
Infections
Taltz may increase the risk of infection. In clinical trials of patients with plaque psoriasis, the Taltz group had a higher rate of infections than the placebo group (27% vs 23%). A similar increase in risk of infection was seen in placebo-controlled trials of patients with psoriatic arthritis. Serious infections have occurred. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue Taltz until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis
Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Taltz. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Taltz. Closely monitor patients receiving Taltz for signs and symptoms of active TB during and after treatment.

Hypersensitivity
Serious hypersensitivity reactions, including angioedema and urticaria (each ≤0.1%), occurred in the Taltz group in clinical trials. Anaphylaxis, including cases leading to hospitalization, has been reported in post-marketing use with Taltz. If a serious hypersensitivity reaction occurs, discontinue Taltz immediately and initiate appropriate therapy.

Inflammatory Bowel Disease
During Taltz treatment, monitor patients for onset or exacerbations of inflammatory bowel disease. Crohn’s disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the Taltz group (Crohn’s disease 0.1%, ulcerative colitis 0.2%) than in the placebo group (0%) during clinical trials in patients with plaque psoriasis.

Immunizations
Prior to initiating therapy with Taltz, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with Taltz.

ADVERSE REACTIONS
Most common adverse reactions (≥1%) associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections. Overall, the safety profile observed in patients with psoriatic arthritis was consistent with the safety profile in patients with plaque psoriasis, with the exception of influenza and conjunctivitis.

Please click to access the Prescribing Information and Medication Guide. Please see Instructions for Use included with the device.
IX HCP ISI 01DEC2017